Ooe Kazuhiro

オオエカズヒロ | Ooe Kazuhiro

Affiliation and department：
Research theme for competitive and other funds (7)：

2022 - 2025 加速器製造可能な新規セラノスティクス核種の開発
2022 - 2025 悪性黒色腫の標的α線治療を指向するAt-211標識薬剤開発
2019 - 2022 Development of At-211-labeled agents targeting the tumor hypoxia region
2019 - 2022 Development of accelerator produced radionuclides for radioisotope therapy application
2019 - 2022 Development of Nuclear Medicine Therapy targeting Cancer Stroma

Show all

Papers (81)：

Sadahiro Naka, Kazuhiro Ooe, Yoshifumi Shirakami, Kenta Kurimoto, Toshihiro Sakai, Kazuhiro Takahashi, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Hiroki Kato, et al. Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial. EJNMMI radiopharmacy and chemistry. 2024. 9. 1. 29-29
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, et al. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI radiopharmacy and chemistry. 2024. 9. 1. 17-17
Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Tadashi Watabe, Kazuhiro Ooe, Xiaojie Yin, Hiromitsu Haba, Kenji Shirasaki, Hidetoshi Kikunaga, Kazuaki Tsukada, et al. Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides. International Journal of Molecular Sciences. 2024. 25. 2. 933-933
Atsushi Yagishita, Miho Katsuragawa, Shin’ichiro Takeda, Yoshifumi Shirakami, Kazuhiro Ooe, Atsushi Toyoshima, Tadayuki Takahashi, Tadashi Watabe. Development and Utility of an Imaging System for Internal Dosimetry of Astatine-211 in Mice. Bioengineering. 2023. 11. 1. 25-25
Tadashi Watabe, Kazuya Kabayama, Sadahiro Naka, Ryuku Yamamoto, Kazuko Kaneda, Satoshi Serada, Kazuhiro Ooe, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, et al. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with⁸⁹Zr or²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma. Journal of Nuclear Medicine. 2023

ｍore...

MISC (36)：

HUANG Xuhao, 加藤弘樹, 角永悠一郎, 下山敦史, 樺山一哉, 片山大輔, 大江一弘, 豊嶋厚史, 羽場宏光, WANG Yang, et al. Synthesis and Evaluation of At-211 Labeled Gold Nanoparticles for Alpha Brachytherapy. 日本放射化学会討論会(Web). 2021. 65th
加藤弘樹, 片山大輔, 大江一弘, 角永悠一郎, 黄栩昊, 下山敦史, 樺山一哉, 深瀬浩一, 畑澤順. 局所投与による癌増殖抑制のためのアスタチン標識金ナノ粒子の最適化. 核医学(Web). 2021. 58. Supplement
片山大輔, 加藤弘樹, 大江一弘, 角永悠一郎, 黄栩昊, 下山敦史, 樺山一哉, 深瀬浩一, 畑澤順. アスタチン-211標識金ナノ粒子局所投与による癌増殖抑制. 核医学(Web). 2021. 58. Supplement
渡部直史, 兼田加珠子, 白神宜史, 大江一弘, 豊嶋厚史, 篠原厚. アスタチンを用いた難治性甲状腺がんに対するアルファ線核医学治療. アイソトープ・放射線研究発表会. 2021. 1. 67
白神宜史, 白神宜史, 白神宜史, 兼田加珠子, 兼田加珠子, 渡部直史, 渡部直史, 大江一弘, 大江一弘, 角永悠一郎, et al. アスタト-脱ボロン酸反応による²¹¹At標識αメチルチロシンの製造と生物活性に関する研究. 核医学(Web). 2021. 58. Supplement

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page